Showing results (1-10 of 200) with videos related to
Sort By:
Pageof 20
Clinical Advances in Hematology & Oncology : H&O|July 4, 2007
Clinical trial designs for multiple myelomaAntje Hoering, John CrowleyClinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2010
Seamless phase I-II trial design for assessing toxicity and efficacy for targeted agentsAntje Hoering, Mike LeBlanc, John CrowleyClinical Trials (London, England)|March 27, 2013
Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agentsAntje Hoering, Alan Mitchell, Michael LeBlanc, et al.Future Oncology (London, England)|April 12, 2017
End points and statistical considerations in immuno-oncology trials: impact on multiple myelomaAntje Hoering, Brian Durie, Hongwei Wang, et al.Blood|October 22, 2008
Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003Madhav V Dhodapkar, Antje Hoering, Morie A Gertz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment armsBart Barlogie, Elias Anaissie, Frits van Rhee, et al.Leukemia & Lymphoma|October 1, 2015
Risk of multiple myeloma in a case-spouse studyGabriella Andreotti, Michael Katz, Antje Hoering, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Randomized phase III clinical trial designs for targeted agentsAntje Hoering, Mike Leblanc, John J CrowleyCancer|October 15, 2010
International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocolsSarah Waheed, John D Shaughnessy, Frits van Rhee, et al.Blood|February 4, 2010
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenanceBijay Nair, Frits van Rhee, John D Shaughnessy, et al.Pageof 20